PATENT CLAIM ANALYSIS

Application Number: 16125317
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["424", "133100"]

Abstract:
Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.

Claim (Index 35):
An isolated antibody that binds to CD40L and that comprises a light chain and a heavy chain, wherein\n (i) the light chain comprises a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with SEQ ID NO:1; (ii) the heavy chain comprises a heavy chain variable region and an Fc region wherein\n a) the heavy chain variable region comprises an amino acid sequence having at least 98% sequence identity with SEQ ID NO:2; and \n b) the Fc region comprises an amino acid sequence having at least 98% sequence identity with SEQ ID NO:3 wherein the Fc region comprises one or a combination of amino acid substitutions selected from the group consisting of C11S, C14S, and P23S.

Metadata:
- Claim Count in Document: 92.0
- Percentile: 97.0
- Lexical Diversity: 1.05
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15667477', '12532517', '14309118', '11871136', '13656922']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7257432584461224
- 35 USC 102 Novelty (BERT): 0.6498589919624962
- Combined Prediction Score: 0.7181548317977599
- Mean Citation Score: 432.208416
- Max Citation Score: 687.2389
- Similarity Product: 566.8497289301396

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test